OTIC Otonomy Inc.

2.59
+0.01  (+0%)
Previous Close 2.58
Open 2.67
Price To Book 1
Market Cap 79475217
Shares 30,685,412
Volume 4,055
Short Ratio
Av. Daily Volume 154,563

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 3Q 2019 with data due 2H 2020.
OTO-413
Hidden hearing loss
Phase 3 data released August 30 failed to meet primary and key secondary endpoints.
OTO-104 AVERTS-1
Meniere's disease
Phase 1/2 trial initiation announced April 11, 2019 with data due 1H 2020.
OTO-313
Tinnitus
Additional Phase 3 trial data due 1H 2020.
OTIVIDEX
Ménière's disease
Phase 2 trial completed October 2016. Phase 3 trial planned.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2 trial initiation announced January 19, 2017.
OTO-104
Prevention of hearing loss in cancer patients undergoing chemotherapy
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Approval announced March 2, 2018.
OTIPRIO
Acute otitis externa

Latest News

  1. Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
  2. The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
  3. Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
  4. Will Otonomy Continue to Surge Higher?
  5. Edited Transcript of OTIC earnings conference call or presentation 4-Mar-19 9:30pm GMT
  6. Those Who Purchased Otonomy Shares Three Years Ago Have A 84% Loss To Show For It
  7. Otonomy to Participate in Two Upcoming Investor Conferences
  8. Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  9. Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update
  10. Analysis: Positioning to Benefit within Apache, A. O. Smith, Diamondback Energy, Maiden, Lands' End, and Otonomy — Research Highlights Growth, Revenue, and Consolidated Results
  11. Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
  12. An Examination Of Otonomy, Inc. (NASDAQ:OTIC)
  13. Otonomy Provides Corporate and Product Pipeline Update
  14. Otonomy to Present at the J.P. Morgan Healthcare Conference
  15. Is Otonomy Inc (NASDAQ:OTIC) Excessively Paying Its CEO?
  16. Otonomy to Participate in Piper Jaffray 30th Annual Healthcare Conference
  17. Report: Developing Opportunities within Control4, Nanometrics, Century Casinos, Steven Madden, Otonomy, and C&J Energy Services — Future Expectations, Projections Moving into 2018
  18. Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
  19. Edited Transcript of OTIC earnings conference call or presentation 5-Nov-18 9:30pm GMT
  20. Otonomy: 3Q Earnings Snapshot